Sinulariolide Suppresses Cell Migration and Invasion by Inhibiting Matrix Metalloproteinase-2/-9 and Urokinase through the PI3K/AKT/mTOR Signaling Pathway in Human Bladder Cancer Cells

Mar Drugs. 2017 Aug 2;15(8):238. doi: 10.3390/md15080238.

Abstract

Sinulariolide is a natural product extracted from the cultured-type soft coral Sinularia flexibilis, and possesses bioactivity against the movement of several types of cancer cells. However, the molecular pathway behind its effects on human bladder cancer remain poorly understood. Using a human bladder cancer cell line as an in vitro model, this study investigated the underlying mechanism of sinulariolide against cell migration/invasion in TSGH-8301 cells. We found that sinulariolide inhibited TSGH-8301 cell migration/invasion, and the effect was concentration-dependent. Furthermore, the protein expressions of matrix metalloproteinases (MMPs) MMP-2 and MMP-9, as well as urokinase, were significantly decreased after 24-h sinulariolide treatment. Meanwhile, the increased expression of tissue inhibitors of metalloproteinases (TIMPs) TIMP-1 and TIMP-2 were in parallel with an increased concentration of sinulariolide. Finally, the expressions of several key phosphorylated proteins in the mTOR signaling pathway were also downregulated by sinulariolide treatment. Our results demonstrated that sinulariolide has significant effects against TSGH-8301 cell migration/invasion, and its effects were associated with decreased levels of MMP-2/-9 and urokinase expression, as well as increased TIMP-1/TIMP-2 expression. The inhibitory effects were mediated by reducing phosphorylation proteins of the PI3K, AKT, and mTOR signaling pathway. The findings suggested that sinulariolide is a good candidate for advanced investigation with the aim of developing a new drug for the treatment of human bladder cancer.

Keywords: PI3K/AKT/mTOR signaling pathway; human bladder cancer; invasion; migration; sinulariolide.

MeSH terms

  • Animals
  • Anthozoa / chemistry
  • Cell Movement / drug effects*
  • Diterpenes / pharmacology*
  • Humans
  • Matrix Metalloproteinases / drug effects*
  • Matrix Metalloproteinases / metabolism
  • Phosphatidylinositol 3-Kinases / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism*
  • Signal Transduction / drug effects
  • TOR Serine-Threonine Kinases / metabolism
  • Tissue Inhibitor of Metalloproteinase-2 / metabolism
  • Urinary Bladder Neoplasms / drug therapy*
  • Urokinase-Type Plasminogen Activator / drug effects*
  • Urokinase-Type Plasminogen Activator / metabolism

Substances

  • Diterpenes
  • TIMP2 protein, human
  • Tissue Inhibitor of Metalloproteinase-2
  • sinulariolide
  • MTOR protein, human
  • Proto-Oncogene Proteins c-akt
  • TOR Serine-Threonine Kinases
  • Urokinase-Type Plasminogen Activator
  • Matrix Metalloproteinases